SynthesisJournal of the European Academy of Dermatology and Venereology : JEADV2025
Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large-scale meta-analysis in immune-mediated inflammatory diseases.
Synthesis in Journal of the European Academy of Dermatology and Venereology : JEADV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large-scale meta-analysis in immune-mediated inflammatory diseases.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- On the heartbreak of anti-tumor necrosis factor drugs.Proceedings (Baylor University. Medical Center) · 2026Article
- TNFR Pathway-Related Proteins and Recurrent Coronary Artery Disease Events.JACC. Advances · 2026Article
- Heart Failure in Rheumatoid Arthritis: Epidemiology, Pathogenesis, Diagnosis, Treatment, and Emerging Insights-A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- When TNF-α becomes a matter of the heart.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent therapeutic guidelines for immune-mediated inflammatory diseases (IMIDs) contraindicate the administration of tumour necrosis factor inhibitors (TNFis) in advanced heart failure (HF) and highlight the potential risk for new-onset HF. The current evidence has low certainty, and the results of studies in the past two decades have even challenged the recommendations regarding the impact of TNFis on the risk of HF.
objectivesThe objective was to systematically synthesize data on the risk of HF in TNFi-treated groups compared to non-treated controls in IMIDs.
methodsA systematic search was conducted in August 2023. Randomized controlled trials (RCTs) and non-randomized observational studies of IMID patients comparing groups receiving TNFis to non-TNFi-exposed controls were included. The outcome was the incidence of worsening, de novo, and composite HF. Random-effects meta-analysis was conducted using risk ratios (RR) with 95% confidence intervals (CIs) to pool data.
resultsThe systematic search identified 49 studies, with 45 included in the quantitative analysis. For the worsening of HF, the pooled results of non-randomized studies showed no statistically significant risk-increasing effect of TNFis (RR = 1.18, 95% CI: 0.69-2.00). Analyses from both RCTs and non-randomized data indicated no increased risk of de novo HF in the TNFi-group compared to controls (RR = 0.87, 95% CI: 0.60-1.25 and RR = 0.86, 95% CI: 0.64-1.14, respectively). Similarly, no increased risk was found for composite (worsening and de novo) HF in the TNFi-treated group versus controls, pooling non-randomized data.
conclusionsOur findings indicate that TNFi-treated IMID patients do not have an increased risk for developing de novo HF, and no statistically significant risk enhancement could be observed in the risk of worsening HF with TNFis. Updating IMID guidelines should be considered regarding TNFis' non-risk increasing effect on de novo HF, whereas further validating data on the risk of worsening HF in TNFi-treated IMID patients is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.